Nonreceptor tyrosine kinases in prostate cancer

被引:101
作者
Chang, Yu-Ming
Kung, Hsing-Jien
Evans, Christopher P. [1 ]
机构
[1] Univ Calif Davis, Dept Urol, Sacramento, CA 95817 USA
[2] Univ Calif Davis, Dept Biol Chem, Sacramento, CA 95817 USA
[3] Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA
来源
NEOPLASIA | 2007年 / 9卷 / 02期
关键词
nonreceptor tyrosine kinase; prostate cancer; Src; FAK; ETK;
D O I
10.1593/neo.06694
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Carcinoma of the prostate (CaP) is the most commonly diagnosed cancer in men in the United States. Signal transduction molecules such as tyrosine kinases play important roles in CaP. Src, a nonreceptor tyrosine kinase (NRTK) and the first proto-oncogene discovered is shown to participate in processes such as cell proliferation and migration in CaP. Underscoring NRTK's and, specifically, Src's importance in cancer is the recent approval by the US Food and Drug Administration of dasatinib, the first commercial Src inhibitor for clinical use in chronic myelogenous leukemia (CML). In this review we will focus on NRTKs and their roles in the biology of CaP. MATERIALS AND METHODS: Publicly available literature from PubMed regarding the topic of members of NRTKs in CaP was searched and reviewed. RESULTS: Src, FAK, JaK1/2, and ETK are involved in processes indispensable to the biology of CaP: cell growth, migration, invasion, angiogenesis, and apoptosis. CONCLUSIONS: Src emerges as a common signaling and regulatory molecule in multiple biological processes in CaP. Src's relative importance in particular stages of CaP, however, required further definition. Continued investigation of NRTKs will increase our understanding of their biological function and potential role as new therapeutic targets.
引用
收藏
页码:90 / 100
页数:11
相关论文
共 130 条
[1]   Links between Fer tyrosine kinase expression levels and prostate cell proliferation [J].
Allard, P ;
Zoubeidi, A ;
Nguyen, LT ;
Tessier, S ;
Tanguay, S ;
Chevrette, M ;
Aprikian, A ;
Chevalier, S .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2000, 159 (1-2) :63-77
[2]  
Allard P, 2000, J ANDROL, V21, P367
[3]   Novel insights into c-Src [J].
Alper, Ö ;
Bowden, ET .
CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (09) :1119-1130
[4]   The role of Src in solid and hematologic malignancies - Development of new-generation Src inhibitors [J].
Alvarez, Ricardo H. ;
Kantarjian, Hagop M. ;
Cortes, Jorge E. .
CANCER, 2006, 107 (08) :1918-1929
[5]  
Aprikian AG, 1997, INT J CANCER, V72, P498, DOI 10.1002/(SICI)1097-0215(19970729)72:3<498::AID-IJC19>3.3.CO
[6]  
2-P
[7]  
ATFI A, 1994, J BIOL CHEM, V269, P30688
[8]   TERMINAL NEUROENDOCRINE DIFFERENTIATION OF HUMAN PROSTATE CARCINOMA-CELLS IN RESPONSE TO INCREASED INTRACELLULAR CYCLIC-AMP [J].
BANG, YJ ;
PIRNIA, F ;
FANG, WG ;
KANG, WK ;
SARTOR, O ;
WHITESELL, L ;
HA, MJ ;
TSOKOS, M ;
SHEAHAN, MD ;
NGUYEN, P ;
NIKLINSKI, WT ;
MYERS, CE ;
TREPEL, JB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (12) :5330-5334
[9]  
Barton BE, 2004, MOL CANCER THER, V3, P11
[10]   IL-6 signaling by STAT3 participates in the change from hyperplasia to neoplasia in NRP-152 and NRP-154 rat prostatic epithelial cells [J].
Barton, BE ;
Murphy, TF ;
Adem, P ;
Watson, RA ;
Irwin, RJ ;
Huang, HF .
BMC CANCER, 2001, 1 (1)